DANIEL SJOSTEDT

ARENTFOX SCHIFF LLP · Washington, DC · registered since 2024

Registered · LDAActive

Send proposal →Contact →Claim this profile →

At a glance

Registered since

2024

Senate LDA system

Clients

last 3 years

Filings

2 agencies contacted

Activity

filings by quarter

Works on

Budget/Appropriations 9 Health Issues 4 Medicare/Medicaid 4 Labor Issues/Antitrust/Workplace 3 Transportation 3 Education 3 Insurance 3 Pharmacy 3 Aviation/Airlines/Airports 3 Trade (domestic/foreign) 2 Telecommunications 2 Medical/Disease Research/Clinical Labs 1 Government Issues 1

Background

Government experience

Staff Assistant

Rep. Jeff Fortenberry

2016-2017

Disclosed on LD-2 filings

Career

ARENTFOX SCHIFF LLP

Washington, DC

2024 - present

Specific issues

Implementation of the Inflation Reduction Act of 2022, regarding USDA telemedicine and distance learning funding Appropriations and grant opportunities for LECOM campuses

Budget/Appropriations · 2024 Q3

Federal legislation and funding opportunities to promote STEM education H. Res. 762, expressing support for increasing the number of Latino students and young professionals entering careers in science, technology, engineering, and mathematics fields Implementation of CHIPS and Science Act regarding funding for STEM programs Department of Education and National Science Foundation policies regarding grants to nonprofit associations

Education · 2024 Q3

H.R. 9026 and S. 4795 (Commerce, Justice, Science, and Related Agencies Appropriations Act, 2025), Title III, regarding National Science Foundation appropriations for STEM education H.R. 9029 and S. 4942 (Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025), regarding Department of Education funding or middle school STEM education

Budget/Appropriations · 2024 Q3

H.R. 2940 and S. 1355 (PASTEUR Act of 2023), all provisions H.R. 4420 (Preparedness and Response Reauthorization Act), all provisions H.R. 4421 (Preparing for all Hazards and Pathogens Reauthorization Act), all provisions S. 2333 (Pandemic and All-Hazards Preparedness and Response Act), all provisions

Medical/Disease Research/Clinical Labs · 2024 Q3

Trade policies affecting market access of Turkish businesses in the United States, including tariff policies

Trade (domestic/foreign) · 2024 Q3

Pharmacy Benefit Manager reform Transparency in prescription drug markets Prescription drug prices S. 1339 (Pharmacy Benefit Manager Reform Act), all provisions H.R. 6283 (DRUG Act), all provisions

Health Issues · 2024 Q3